Related Experiment Video

Updated: May 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Pharmacological treatment of patients with advanced prostate cancer

B Turner1, L Drudge-Coates

  • 1Homerton University Hospital, London and Barts Health Hospitals, London.

Nursing Standard (Royal College of Nursing (Great Britain) : 1987)
|February 6, 2014
PubMed

Insights

Androgen deprivation therapy manages advanced prostate cancer by reducing testosterone. This article compares luteinising hormone-releasing hormone agonists with newer gonadotrophin-releasing hormone (GnRH) antagonists for nurses.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Prostate cancer growth is linked to testosterone, a male sex hormone.
  • Androgen deprivation therapy (ADT) is a standard treatment for advanced prostate cancer, effectively managing symptoms and causing tumor regression.
  • Luteinising hormone-releasing hormone (LHRH) agonists are widely used for ADT, but newer gonadotrophin-releasing hormone (GnRH) antagonists are emerging.

Purpose of the Study:

  • To elucidate the differences between LHRH agonists and GnRH antagonists in prostate cancer management.
  • To equip nurses with essential knowledge for patient education and effective administration of GnRH antagonist therapy.

Main Methods:

  • Comparative review of existing literature on LHRH agonists and GnRH antagonists for prostate cancer.
  • Focus on mechanisms of action, clinical efficacy, side effect profiles, and administration protocols.

Main Results:

  • GnRH antagonists offer a distinct mechanism of action compared to LHRH agonists, potentially leading to different clinical outcomes and side effect profiles.
  • Understanding these differences is crucial for optimizing patient care and treatment selection in advanced prostate cancer.

Conclusions:

  • GnRH antagonists represent a significant advancement in ADT for prostate cancer.
  • Nurses play a vital role in educating patients about GnRH antagonists and ensuring proper administration, thereby improving treatment adherence and outcomes.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K